Top

International Journal of Clinical Oncology

Published in:

01-11-2019 | Cervical Cancer | Original Article

Neoadjuvant chemotherapy followed by radical hysterectomy for stage IB2-to-IIB cervical cancer: a retrospective cohort study

Authors: Lei Li, Ming Wu, Shuiqing Ma, Xianjie Tan, Sen Zhong

Published in: International Journal of Clinical Oncology | Issue 11/2019

Abstract

Introduction

This study was to evaluate the surgical and survival effects of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) for cervical cancer with stages IB2 to IIB of FIGO 2009 staging.

Methods

From February 2, 2001 to November 11, 2015, 428 patients received NAC followed by RH in a tertiary hospital, in which all the major procedures were performed by one surgeon. Surgical and survival outcomes were evaluated between the NAC and primary RH groups.

Results

A total of 279 (65.2%) patients received NAC, and the overall clinical and complete pathological response rates were 65.9% and 10.8%, respectively. Compared with primary RH patients, NAC patients had more advanced stages, higher recurrence rate, longer median duration of RH, and more median estimated blood loss. After adjusted with baseline risk factors, no significant differences in progression-free or overall survival were observed between the NAC and primary RH groups. However, the responders to NAC had better survival outcomes.

Conclusions

There were no surgical or survival benefits of NAC for patients with cervical cancer of stages IB2 to IIB except for the responders to NAC.

Available only for authorised users

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30. https://doi.org/10.3322/caac.21332 CrossRef

Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132. https://doi.org/10.3322/caac.21338 CrossRefPubMed

deSouza NM, Soutter WP, Rustin G et al (2004) Use of neoadjuvant chemotherapy prior to radical hysterectomy in cervical cancer: monitoring tumour shrinkage and molecular profile on magnetic resonance and assessment of 3-year outcome. Br J Cancer 90:2326–2331. https://doi.org/10.1038/sj.bjc.6601870 CrossRefPubMedPubMedCentral

Panici PB, Bellati F, Plotti F et al (2008) Neoadjuvant chemotherapy followed by radical surgery in patients affected by vaginal carcinoma. Gynecol Oncol 111:307–311. https://doi.org/10.1016/j.ygyno.2008.07.005 CrossRef

Katsumata N, Yoshikawa H, Kobayashi H et al (2013) Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer 108:1957–1963. https://doi.org/10.1038/bjc.2013.179 CrossRefPubMedPubMedCentral

Yang Z, Chen D, Zhang J et al (2016) The efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer: a randomized multicenter study. Gynecol Oncol 141:231–239. https://doi.org/10.1016/j.ygyno.2015.06.027 CrossRefPubMed

Kim HS, Sardi JE, Katsumata N et al (2013) Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis. Eur J Surg Oncol 39:115–124. https://doi.org/10.1016/j.ejso.2012.09.003 CrossRefPubMed

Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration (2010) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev 26:CD008285. https://doi.org/10.1002/14651858.cd008285 CrossRef

Minig L, Patrono MG, Romero N et al (2014) Different strategies of treatment for uterine cervical carcinoma stage IB2–IIB. World J Clin Oncol 5:86–92. https://doi.org/10.5306/wjco.v5.i2.86 CrossRefPubMedPubMedCentral

10.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®). Cervical cancer. Version 2.2019—October 12, 2018. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Accessed 15 Dec 2018

11.

Nama V, Angelopoulos G, Twigg J et al (2018) Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage IB2 cervical cancer. Cochrane Database Syst Rev 10:CD011478. https://doi.org/10.1002/14651858.CD011478.pub2 CrossRefPubMed

12.

Gupta S, Maheshwari A, Parab P et al (2018) Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol 36:1548–1555. https://doi.org/10.1200/JCO.2017.75.9985 CrossRefPubMed

13.

Cibula D, Abu-Rustum NR, Benedetti-Panici P et al (2011) New classification system of radical hysterectomy: emphasis on a three-dimensional anatomic template for parametrial resection. Gynecol Oncol 122:264–268. https://doi.org/10.1016/j.ygyno.2011.04.029 CrossRefPubMed

14.

Querleu D, Morrow CP (2008) Classification of radical hysterectomy. Lancet Oncol 9:297–303. https://doi.org/10.1016/s1470-2045(08)70074-3 CrossRefPubMed

15.

Li L, Ma S, Tan X et al (2019) The urodynamics and survival outcomes of different methods of dissecting the inferior hypogastric plexus in laparoscopic nerve-sparing radical hysterectomy of type C: a randomized controlled study. Ann Surg Oncol 26:1560. https://doi.org/10.1245/s10434-019-07228-8 CrossRefPubMed

16.

Pecorelli S, Zigliani L, Odicino F (2009) Revised FIGO staging for carcinoma of the cervix. Int J Gynecol Obstet 105:107–108. https://doi.org/10.1016/j.ijgo.2009.02.009 CrossRef

17.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRef

18.

Testa AC, Moro F, Pasciuto T et al (2018) PRospective Imaging of CErvical cancer and neoadjuvant treatment (PRICE) study: role of ultrasound to assess residual tumor in locally advanced cervical cancer patients undergoing chemoradiation and radical surgery. Ultrasound Obstet Gynecol 52:110–118. https://doi.org/10.1002/uog.18953 CrossRefPubMed

19.

Obermair A, Gebski V, Frumovitz M et al (2008) A phase III randomized clinical trial comparing laparoscopic or robotic radical hysterectomy with abdominal radical hysterectomy in patients with early stage cervical cancer. J Minim Invasive Gynecol 15:584–588. https://doi.org/10.1016/j.jmig.2008.06.013 CrossRefPubMed

20.

Common Terminology Criteria for Adverse Events (CTCAE) v4.03. National Cancer Institute. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. Accessed 15 Dec 2018

21.

Shimada M, Nagao S, Fujiwara K et al (2016) Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix. Int J Clin Oncol 21:1128–1135. https://doi.org/10.1007/s10147-016-1010-0 CrossRefPubMed

22.

Gadducci A, Landoni F, Cosio S et al (2018) Neoadjuvant platinum-based chemotherapy followed by radical hysterectomy for stage Ib2–IIb adenocarcinoma of the uterine cervix—an Italian Multicenter Retrospective Study. Anticancer Res 38:3627–3634. https://doi.org/10.21873/anticanres.12637 CrossRefPubMed

23.

Tsubamoto H, Maeda H, Kanazawa R et al (2013) Phase II trial on neoadjuvant intravenous and trans-uterine arterial chemotherapy for locally advanced bulky cervical adenocarcinoma. Gynecol Oncol 129:129–134. https://doi.org/10.1016/j.ygyno.2013.01.007 CrossRefPubMed

24.

Junker P, Puppe J, Thangarajah F et al (2018) Neoadjuvant therapy of cervical carcinoma with the angiogenesis inhibitor bevacizumab: a single-centre analysis. Geburtshilfe Frauenheilkd 78:768–774. https://doi.org/10.1055/a-0641-5588 CrossRefPubMedPubMedCentral

25.

Rydzewska L, Tierney J, Vale CL et al (2012) Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 12:CD007406. https://doi.org/10.1002/14651858.CD007406.pub3 CrossRefPubMed

26.

Mossa B, Mossa S, Corosu L et al (2010) Follow-up in a long-term randomized trial with neoadjuvant chemotherapy for squamous cell cervical carcinoma. Eur J Gynaecol Oncol 31:497–503PubMed

27.

Kokka F, Bryant A, Brockbank E et al (2015) Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database Syst Rev 4:CD010260. https://doi.org/10.1002/14651858.CD010260.pub2 CrossRef

28.

Wen H, Wu X, Li Z et al (2012) A prospective randomized controlled study on multiple neoadjuvant treatments for patients with stage IB2 to IIA cervical cancer. Int J Gynecol Cancer 22:296–302. https://doi.org/10.1097/IGC.0b013e31823610a1 CrossRefPubMed

29.

Shoji T, Takatori E, Furutake Y et al (2016) Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass. Int J Clin Oncol 21:1120–1127. https://doi.org/10.1007/s10147-016-1008-7 CrossRefPubMedPubMedCentral

30.

Mahmoud O, Einstein MH (2018) Which patients with cervical squamous cell carcinoma might benefit from neoadjuvant chemotherapy? J Clin Oncol 36:1543–1547. https://doi.org/10.1200/JCO.2017.77.3416 CrossRefPubMed

31.

Marchetti C, De Felice F, Di Pinto A et al (2018) Survival nomograms after curative neoadjuvant chemotherapy and radical surgery for stage IB2–IIIB cervical cancer. Cancer Res Treat 50:768–776. https://doi.org/10.4143/crt.2017.141 CrossRefPubMed

32.

Pergialiotis V, Rodolakis A, Christakis D et al (2013) Laparoscopically assisted vaginal radical hysterectomy: systematic review of the literature. J Minim Invasive Gynecol 20:745–753. https://doi.org/10.1016/j.jmig.2013.04.021 CrossRefPubMed

33.

Bentivegna E, Maulard A, Pautier P et al (2016) Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature. Fertil Steril 106:1195–1211. https://doi.org/10.1016/j.fertnstert.2016.06.032 CrossRefPubMed

34.

Plante M (2015) Bulky early-stage cervical cancer (2–4 cm lesions): upfront radical trachelectomy or neoadjuvant chemotherapy followed by fertility-preserving surgery: which is the best option? Int J Gynecol Cancer 25:722–728. https://doi.org/10.1097/IGC.0000000000000410 CrossRefPubMed

35.

Li J, Wang LJ, Zhang BZ et al (2011) Neoadjuvant chemotherapy with paclitaxel plus platinum for invasive cervical cancer in pregnancy: two case report and literature review. Arch Gynecol Obstet 284:779–783. https://doi.org/10.1007/s00404-011-1943-5 CrossRefPubMed

36.

Fruscio R, Villa A, Chiari S et al (2012) Delivery delay with neoadjuvant chemotherapy for cervical cancer patients during pregnancy: a series of nine cases and literature review. Gynecol Oncol 126:192–197. https://doi.org/10.1016/j.ygyno.2012.04.027 CrossRefPubMed

37.

Tang J, Tang Y, Yang J et al (2012) Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma. Gynecol Oncol 125:297–302. https://doi.org/10.1016/j.ygyno.2012.01.033 CrossRefPubMed

38.

Lan M, Chen C, Huang Y et al (2017) Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis. Sci Rep 7:42624. https://doi.org/10.1038/srep42624 CrossRefPubMedPubMedCentral

39.

Ferrandina G, Palluzzi E, Gallotta V et al (2018) Neo-adjuvant platinum-based chemotherapy followed by chemoradiation and radical surgery in locally advanced cervical cancer (Lacc) patients: a phase II study. Eur J Surg Oncol 44:1062–1068. https://doi.org/10.1016/j.ejso.2018.04.019 CrossRefPubMed

40.

Ferrandina G, Corrado G, Vitrano G et al (2018) Dose-dense paclitaxel/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study. Cancer Chemother Pharmacol 83:431. https://doi.org/10.1007/s00280-018-3742-1 CrossRefPubMed

41.

Ramirez PT, Frumovitz M, Pareja R et al (2018) Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med 379:1895–1904. https://doi.org/10.1056/NEJMoa1806395 CrossRefPubMed

42.

Melamed A, Margul DJ, Chen L et al (2018) Survival after minimally invasive radical hysterectomy for early-stage cervical cancer. N Engl J Med 379:1905–1914. https://doi.org/10.1056/NEJMoa1804923 CrossRefPubMedPubMedCentral

Title: Neoadjuvant chemotherapy followed by radical hysterectomy for stage IB2-to-IIB cervical cancer: a retrospective cohort study
Authors: Lei Li
Ming Wu
Shuiqing Ma
Xianjie Tan
Sen Zhong
Publication date: 01-11-2019
Publisher: Springer Singapore
Keywords: Cervical Cancer
Cervical Cancer
Hysterectomy
Cytostatic Therapy
Published in: International Journal of Clinical Oncology / Issue 11/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01510-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2019

Comparison of computed tomography imaging analyses for evaluation after chemotherapy in patients with colorectal cancer: a retrospective pooled analysis of six phase II clinical trials

Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study

Efficacy of daikenchuto, a traditional Japanese Kampo medicine, for postoperative intestinal dysfunction in patients with gastrointestinal cancers: meta-analysis

Forkhead box protein O1 (FOXO1) and paired box gene 3 (PAX3) overexpression is associated with poor prognosis in patients with cervical cancer

Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil–tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial

CDC20 and its downstream genes: potential prognosis factors of osteosarcoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer